Acute Pancreatitis Associated With Blinatumomab Treatment in a Patient With Acute Lymphoblastic Leukemia

Blinatumomab, a bispecific T-cell engager, has significantly advanced the treatment of relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL), with well-established toxicities such as cytokine release syndrome and neurotoxicity. However, pancreatitis remains an exceptionally rare and underrecognized adverse effect, with limited reports outside of clinical trials. This case report presents one of the first documented instances of acute pancreatitis in a patient receiving blinatumomab in a real-world setting, diagnosed by elevated serum lipase and confirmatory CT imaging. The patient's presentation and resolution with supportive care underscore the importance of promptly recognizing and managing this potential complication. Further investigation is warranted to elucidate the pathophysiological mechanisms of this association and to guide clinical decisions regarding blinatumomab safety and rechallenge protocols in affected patients.